Table 2 Incremental cost effectiveness ratios, mean results (all patients considered)
From: Cost-utility analysis of imrecoxib compared with diclofenac for patients with osteoarthritis
Treatment | Cost($)/per patient | QALYs/per patient | ICER (â–łC/â–łE) | Comparator |
|---|---|---|---|---|
Patients aged 55 years old (lower risk of GI and CV events) | ||||
Diclofenac | 1298.73 | 4.16 | – | – |
Diclofenac + PPI | 1767.47 | 5.63 | 320.83 | Diclofenac |
Imrecoxib | 1894.66 | 5.65 | 401.58 | Diclofenac |
Imrecoxib + PPI | 2181.21 | 5.68 | 8656.09 | Imrecoxib |
Imrecoxib + PPI | – | – | 8274.80 | Diclofenac + PPI |
Patients aged 65 years old (higher risk of GI and CV events) | ||||
Diclofenac | 1373.86 | 3.37 | – | – |
Diclofenac + PPI | 1773.89 | 4.47 | 363.61 | Diclofenac |
Imrecoxib | 1927.92 | 4.50 | 492.77 | Diclofenac |
Imrecoxib + PPI | 2194.59 | 4.53 | 8178.07 | Imrecoxib |
Imrecoxib + PPI | – | – | 7011.67 | Diclofenac + PPI |